AstraZeneca wins FDA approval for immunotherapy drug

The Food and Drug Administration approved AstraZencea's immunotherapy drug, Imfinzi, as a treatment for bladder cancer.

Imfinzi may be used to treat patients with advanced cancer bladder whose illness has advanced despite chemotherapy. The average wholesale acquisition price for the drug is about $15,000 a month, according to AstraZeneca.

While this decision marks the first approved use for the immunotherapy drug, AstraZeneca is also exploring Imfinzi's efficacy to treat lung cancer.

More articles on supply chain:

FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.